SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Pre-commercialization of circadian clock-drug interactions screening tool for therapeutic applications

The CIRCOMMUNICATION project aims to commercialize CircaSCOPE, a high-throughput method for constructing Phase Transition Curves to enhance drug efficacy and minimize side effects through chronotherapy.

Subsidie
€ 150.000
2022

Projectdetails

Introduction

Circadian clocks carry immense importance to human health, as clock disruption is related to various malignancies from sleep disorders through diabetes to cancer. Furthermore, many drug targets are influenced by circadian clocks. In order to maximize a drug’s efficacy while minimizing side effects, it is necessary to consider the drug’s time-of-administration, also known as “chronotherapy.” These revelations are critical for drug administration and development.

Challenges in Implementation

However, their practical implementation is tempered by the lack of suitable research tools that bridge the gap from the bench to the clinic. The time-dependent effect of an intervention on the clock is represented by the Phase Transition Curve (PTC). PTC retrieval is laborious and challenging; consequently, they were mostly overlooked in the pharmaceutical R&D process.

Project Overview

In the ERC Project CIRCOMMUNICATION, we studied clock-resetting mechanisms, which led to the development of CircaSCOPE, an efficient high-throughput methodology for high-resolution PTC construction. CircaSCOPE can be used as a powerful screening method for clock-modulating drugs, either for the purpose of:

  1. Targeting pathologies associated with circadian disruption
  2. Identifying drugs which elicit unwanted side effects on the clock

Once fully developed and systematically integrated into chrono-medicine, CircaSCOPE has the potential to improve drug discovery and yield medicines with a better therapeutic index.

Commercialization Plan

Here, we detail our plan for the first steps toward the commercialization of our innovation. We will demonstrate the applicability of this approach through drug library screens and expand the repertoire of cell types that the system relies on.

Future Directions

In addition, we will explore different commercialization strategies and interact with potential stakeholders and end-users. Given the medical importance of circadian effects, we envision that CircaSCOPE will become a gold-standard procedure in future drug development.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-4-2022
Einddatum30-9-2023
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • WEIZMANN INSTITUTE OF SCIENCEpenvoerder

Land(en)

Israel

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Targeting the circadian clock in personalized disease prevention

This project aims to identify and mitigate health risks associated with disrupted circadian rhythms in night workers through genetic profiling and targeted interventions for healthier aging.

ERC Advanced...€ 2.499.965
2022
Details

Co-option of host circadian rhythms in cancer

INN-TIME aims to uncover how tumors exploit circadian rhythms of innate immune and stromal cells to evade anti-tumoral defenses, paving the way for novel cancer therapies.

ERC Starting...€ 1.500.000
2024
Details

The early ticking of the central circadian pacemaker: when and how

StarTicking aims to uncover the development and functionality of the circadian clock in mice and humans, linking early environmental factors to behavioral outcomes in pre-term infants.

ERC Consolid...€ 1.955.875
2024
Details

Circadian rhythm: from preclinical to post-diagnosis dementia

The RHYTHM IN DEMENTIA project aims to identify circadian rhythm features linked to dementia risk and progression, using accelerometry and biomarkers to inform prevention strategies.

ERC Consolid...€ 1.999.982
2023
Details

Accurate quantification of neurologic disease over time

The project aims to develop CHRONOS, an AI-driven diagnostic tool using synthetic biomaps to enable earlier and more accurate detection of brain tumors, facilitating timely clinical decisions.

ERC Proof of...€ 150.000
2025
Details
ERC Advanced...

Targeting the circadian clock in personalized disease prevention

This project aims to identify and mitigate health risks associated with disrupted circadian rhythms in night workers through genetic profiling and targeted interventions for healthier aging.

ERC Advanced Grant
€ 2.499.965
2022
Details
ERC Starting...

Co-option of host circadian rhythms in cancer

INN-TIME aims to uncover how tumors exploit circadian rhythms of innate immune and stromal cells to evade anti-tumoral defenses, paving the way for novel cancer therapies.

ERC Starting Grant
€ 1.500.000
2024
Details
ERC Consolid...

The early ticking of the central circadian pacemaker: when and how

StarTicking aims to uncover the development and functionality of the circadian clock in mice and humans, linking early environmental factors to behavioral outcomes in pre-term infants.

ERC Consolidator Grant
€ 1.955.875
2024
Details
ERC Consolid...

Circadian rhythm: from preclinical to post-diagnosis dementia

The RHYTHM IN DEMENTIA project aims to identify circadian rhythm features linked to dementia risk and progression, using accelerometry and biomarkers to inform prevention strategies.

ERC Consolidator Grant
€ 1.999.982
2023
Details
ERC Proof of...

Accurate quantification of neurologic disease over time

The project aims to develop CHRONOS, an AI-driven diagnostic tool using synthetic biomaps to enable earlier and more accurate detection of brain tumors, facilitating timely clinical decisions.

ERC Proof of Concept
€ 150.000
2025
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

Leveraging CRISPR-Cas for fast and accurate point-of-care diagnostics

Scope Biosciences aims to validate its patented CRISPR-Cas diagnostic technology, scopeDx, for rapid, accurate, and adaptable point-of-care diagnostics in healthcare.

EIC Transition€ 2.498.125
2024
Details

Artificial Intelligence Chrono Sunglasses

Het project ontwikkelt AI Chrono Zonnebrillen voor Parkinson-patiënten om lichttherapie te optimaliseren en hun kwaliteit van leven te verbeteren.

Mkb-innovati...€ 350.000
2021
Details

Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development

Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.

EIC Accelerator€ 2.499.831
2024
Details

Voorkomen van therapieresistentie bij kanker

Dit project onderzoekt een bloedgebaseerde methode voor vroege detectie van therapieresistentie bij kanker om levensverwachting te verbeteren.

Mkb-innovati...€ 20.000
2021
Details

Bringing 3D cardiac tissues to high throughput for drug discovery screens

Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.

EIC Transition€ 1.457.500
2023
Details
EIC Transition

Leveraging CRISPR-Cas for fast and accurate point-of-care diagnostics

Scope Biosciences aims to validate its patented CRISPR-Cas diagnostic technology, scopeDx, for rapid, accurate, and adaptable point-of-care diagnostics in healthcare.

EIC Transition
€ 2.498.125
2024
Details
Mkb-innovati...

Artificial Intelligence Chrono Sunglasses

Het project ontwikkelt AI Chrono Zonnebrillen voor Parkinson-patiënten om lichttherapie te optimaliseren en hun kwaliteit van leven te verbeteren.

Mkb-innovatiestimulering Topsectoren R&D Samenwerking
€ 350.000
2021
Details
EIC Accelerator

Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development

Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.

EIC Accelerator
€ 2.499.831
2024
Details
Mkb-innovati...

Voorkomen van therapieresistentie bij kanker

Dit project onderzoekt een bloedgebaseerde methode voor vroege detectie van therapieresistentie bij kanker om levensverwachting te verbeteren.

Mkb-innovatiestimulering Topsectoren Haalbaarheid
€ 20.000
2021
Details
EIC Transition

Bringing 3D cardiac tissues to high throughput for drug discovery screens

Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.

EIC Transition
€ 1.457.500
2023
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.